title: MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias.
abstract: CXCR4 is a negative prognostic marker in acute myeloid leukemias (AMLs). Therefore, it is necessary to develop novel ways to inhibit CXCR4 expression in leukemia. AMD3100 is an inhibitor of CXCR4 currently used to mobilize cancer cells. CXCR4 is a target of microRNA (miR)-146a that may represent a new tool to inhibit CXCR4 expression. We then investigated CXCR4 regulation by miR-146a in primary AMLs and found an inverse correlation between miR-146a and CXCR4 protein expression levels in all AML subtypes. As the lowest miR-146a expression levels were observed in M5 AML, we analyzed the control of CXCR4 expression by miR-146a in normal and leukemic monocytic cells and showed that the regulatory miR-146a/CXCR4 pathway operates during monocytopoiesis, but is deregulated in AMLs. AMD3100 treatment and miR-146a overexpression were used to inhibit CXCR4 in leukemic cells. AMD3100 treatment induces the decrease of CXCR4 protein expression, associated with miR-146a increase, and increases sensitivity of leukemic blast cells to cytotoxic drugs, this effect being further enhanced by miR-146a overexpression. Altogether our data indicate that miR-146a and AMD3100, acting through different mechanism, downmodulate CXCR4 protein levels, impair leukemic cell proliferation and then may be used in combination with anti-leukemia drugs, for development of new therapeutic strategies.
authors: I
authors: I
authors: Spinello
authors: M T
authors: MT
authors: Quaranta
authors: R
authors: R
authors: Riccioni
authors: V
authors: V
authors: Riti
authors: L
authors: L
authors: Pasquini
authors: A
authors: A
authors: Boe
authors: E
authors: E
authors: Pelosi
authors: A
authors: A
authors: Vitale
authors: R
authors: R
authors: Foà
authors: U
authors: U
authors: Testa
authors: C
authors: C
authors: Labbaye